dr. mesa on emerging therapies in myelofibrosis
Published 3 years ago • 68 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:13
dr. mesa on new trials and agents in the pipeline in myelofibrosis
-
1:52
dr. mesa on investigative therapies in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
1:48
dr. mesa on pacritinib for myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:10
dr. ruben mesa on comfort-1 for myelofibrosis
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
2:00
dr. mascarenhas on approved and emerging treatment options in myelofibrosis
-
0:55
dr. mesa on intended patients with myelofibrosis for pacritnib
-
1:33
dr. mesa on late-stage trials in myelofibrosis
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
2:13
dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis